Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...
PharmExec11d
Funding Roundup: Recent Financing Rounds Completed for Pain, Cancer, and Musculoskeletal Care Innovations
Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...
The MSU Exponent2d
Virtual Reality Headsets Can Help Ease Cancer Pain
FRIDAY, March 28, 2025 (HealthDay News) -- Virtual reality (VR) might be able to provide cancer patients significant pain ...
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for ...